APC and cancer: Most common are loss of function mutations in APC, which account for 60-80% of Wnt pathway aberrations in colorectal cancers (Kinzler & Vogelstein, 1996; Kleeman et al., 2020; Yaeger et al., 2018), and to a lesser extent, aberrations in other downstream components AXIN1, AXIN2, and CTNNB1. In APC-mutated cancer models, restoration of functional APC protein is effective in reversing tumorigenesis (Dow et al., 2015; Faux et al., 2004; Zilberberg, Lahav, & Rosin-Arbesfeld, 2010), but with current technologies, APC restoration is not a practical therapeutic option.